

## **REMARKS**

Claims 1 – 158 are cancelled without prejudice.

New claims 59 – 220 are added.

The new claims are supported in the text of US patent 6,643,347 as follows:

Claim 159 is supported in columns 17-18 where peptide vaccine compositions are described.

Claim 160 is supported in column 13 where substitutions, additions and deletions are discussed.

Claim 161 is supported in column 20 where modified sequences are discussed that differ by no more than about 20% from the original sequence.

Claim 162 is supported in column 20 where modifications in hydrophobicity are discussed.

Claim 163 is supported in column 20 and 22 amphipathic helix structures are discussed.

Claim 164 is supported in column 22 where the location of hydrophobic and hydrophilic parts of the peptide are discussed.

Claim 165 is supported in column 22 where susceptibility to cleavage is discussed.

Claim 166 is supported in column 20 where amino-terminal acetylation, carboxy-terminal amidation, amino-terminal cysteine addition, and carboxy-terminal cysteine addition are discussed.

Claim 167 is supported in column 20 where D isomer substitutions are discussed.

Claim 168 is supported in column 21 where carrier molecules are discussed.

Claim 169 is supported in column 21.

Claims 170–176 are supported in the background and throughout the specification .

Claim 177 is supported in column 10 where various peptide fragments are discussed.

Claim 178 is supported in columns 12-13 and 38-39 where a carbohydrate-depleted polypeptide is discussed.

Claim 179 is supported in column 12 and 38-39 and throughout the specification.

Claims 180-182 are supported in column 8.

Claim 183 is supported in columns 17-18 that discusses compositions comprising peptides (plural).

Claim 184 is supported in columns 17-18 where peptides are described as stimulating immunogenicity and producing an immune reaction that arrests infection.

Claim 185 is supported in columns 3-4 and 7-8 and 42 where immunological mimicry is discussed.

Claim 186 is supported near the end of column 8.

Claim 187 – 188 are supported in columns 3-4.

Claim 189-196 is supported at columns 13-14 where synthetic gene production and gene expression vectors are discussed wherein the genes encode the immunogenic peptides of the invention.

Claim 197 is supported in columns 17-18 and throughout the specification.

Claim 201 is supported in columns 17-18 and 20.

Claim 202-204 are supported in column 20 and 38 et seq., where carbohydrate depletion and modifications in hydrophobicity are discussed.

Claim 205 is supported in columns 10-11 and 45 that discuss various HIV proteins.

Claim 206-207 are supported in columns 21 and 31 where adjuvants (e.g. MDP) are discussed.

Claim 208 is supported at the top of column 47 where daily infusion of a vaccine (to a subject) is discussed.

Claim 209-220 are method claims and are supported in columns 13-14, 17-18, and as for corresponding composition claims above, and additionally in the examples.


### **CONCLUSION**

No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

If a telephone conference would expedite allowance of the claims, Applicants invite the Examiner to contact Applicants' Attorney.

Should anything further be required, a telephone call to the undersigned, at (312) 226-1818, is respectfully invited.

Respectfully submitted,  
FACTOR & PARTNERS, LLC

A handwritten signature in black ink, appearing to read "A. Bell", is written over a horizontal line.

Dated: October 24, 2003

Adam W. Bell  
One of Attorneys for Applicant